We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$961M
AUM Growth
+$374M
Cap. Flow
+$41.2M
Cap. Flow %
4.29%
Top 10 Hldgs %
44.93%
Holding
194
New
69
Increased
29
Reduced
39
Closed
48

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.6M
2
AGN
Allergan plc
AGN
+$24.2M
3
MRK icon
Merck
MRK
+$22.3M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
ENDP
Endo International plc
ENDP
+$17.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$33.6M
2
SHPG
Shire pic
SHPG
+$20.7M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.2M
4
BIIB icon
Biogen
BIIB
+$11.8M
5
ISRL
Isramco Inc
ISRL
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 59.2%
2 Miscellaneous 33.43%
3 Technology 2.61%
4 Industrials 1.8%
5 Consumer Discretionary 1.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$20.3B
$110M 11.43%
+8,300
New +$755K
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$805B
$72.3M 7.52%
+3,500
New +$722K
AGN
3
DELISTED
Allergan plc
AGN
$57.2M 5.95%
192,100
+85,000
+79% +$24.2M
PFE icon
4
Pfizer
PFE
$158B
$35.6M 3.71%
1,079,310
+158,100
+17% +$5.03M
XNTK icon
5
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.92B
$33.1M 3.44%
+3,000
New +$152K
GILD icon
6
Gilead Sciences
GILD
$186B
$31.4M 3.27%
320,000
+130,000
+68% +$13.2M
TEVA icon
7
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$25.1M 2.61%
402,819
+6,550
+2% +$381K
ABBV icon
8
AbbVie
ABBV
$465B
$23.8M 2.48%
+407,000
New +$24.6M
TEVA icon
9
CALL
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$21.8M 2.27%
3,500
-460,700
-99% -$26.8M
MRK icon
10
Merck
MRK
$363B
$21.6M 2.24%
+393,000
New +$22.3M
AMGN icon
11
Amgen
AMGN
$204B
$19.2M 2%
120,200
+111,650
+1,306% +$17.6M
ENDP
12
DELISTED
Endo International plc
ENDP
$18.8M 1.96%
+210,000
New +$17.6M
VTRS icon
13
Viatris
VTRS
$19.7B
$16.1M 1.68%
272,100
+175,000
+180% +$9.98M
ASPX
14
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$12.5M 1.31%
125,074
+15,000
+14% +$999K
ORA icon
15
Ormat Technologies
ORA
$5.97B
$12.1M 1.25%
80,092
-228,908
-74% -$7.18M
AMAG
16
DELISTED
AMAG Pharmaceuticals
AMAG
$10.9M 1.14%
200,230
+75,000
+60% +$3.57M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$12.7B
$9.97M 1.04%
80,000
– –
NVS icon
18
Novartis
NVS
$268B
$9.86M 1.03%
111,600
-379,017
-77% -$33.6M
XLV icon
19
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.8B
$9.43M 0.98%
+1,300
New +$92.7K
BHC icon
20
Bausch Health
BHC
$2.12B
$9.09M 0.95%
45,750
-52,800
-54% -$9.37M
UTHR icon
21
United Therapeutics
UTHR
$21.2B
$8.42M 0.88%
48,840
-25,000
-34% -$3.81M
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
$8.35M 0.87%
112,455
+30,500
+37% +$2.15M
CELG
23
DELISTED
Celgene Corp
CELG
$8.07M 0.84%
+70,000
New +$8.36M
VRNT
24
DELISTED
Verint Systems
VRNT
$7.57M 0.79%
240,083
-46,727
-16% -$1.37M
SHPG
25
DELISTED
Shire pic
SHPG
$7.23M 0.75%
134,751
-90,000
-40% -$20.7M
1
2 3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sphera Funds Management held 194 positions worth $961M, up 64% from $587M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $41.2M of net new capital in Q1 2015, opening 69 new positions and adding to 29 existing holdings. Its largest new stake was AbbVie: 407,000 shares worth $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 69% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Novartis, an estimated $33.6M trimmed.

  • Sphera Funds Management's largest Q1 2015 buy was AbbVie: 407,000 shares worth $23.8M.
  • Sphera Funds Management added most to Allergan plc in Q1 2015, an estimated $24.2M increase.
  • Sphera Funds Management's biggest Q1 2015 reduction was Novartis, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q1 2015, selling an estimated $18.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $961M portfolio in Q1 2015.
  • Sphera Funds Management opened 69 new positions and closed 48 in Q1 2015.
  • Sphera Funds Management's portfolio value rose 64% quarter-over-quarter to $961M.

Based on Sphera Funds Management's 13F filing for Q1 2015, filed 11 May 2015.